Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | TEAD1 | P28347 | 4/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | IDH2 | P48735 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 4/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21787541 | 0.84 | PIK3CD (0.39) | PIK3CDMCHR1TEAD1JAK3BTK | |
| SCHEMBL20322723 | 0.83 | JAK3 (0.40) | MCHR1TEAD1IDH1IDH2TEAD3 | |
| SCHEMBL26227804 | 0.81 | PIK3CD (0.49) | PIK3CDMCHR1HSD17B10KDM4E | |
| SCHEMBL21106061 | 0.80 | MCHR1 (0.47) | PIK3CDMCHR1HSD17B10KDM4E | |
| SCHEMBL31387583 | 0.79 | L3MBTL3 (0.51) | TEAD1TEAD3JAK3BTKDCUN1D1 | |
| SCHEMBL31387587 | 0.79 | L3MBTL3 (0.51) | TEAD1TEAD3JAK3BTKDCUN1D1 | |
| SCHEMBL21106943 | 0.78 | PIK3CD (0.46) | PIK3CDMCHR1HSD17B10KDM4E | |
| SCHEMBL25663931 | 0.78 | PIK3CD (0.49) | PIK3CDMCHR1HSD17B10KDM4E | |
| SCHEMBL25883657 | 0.77 | POLB (0.46) | PIK3CDMCHR1HSD17B10KDM4E | |
| SCHEMBL21787327 | 0.76 | TEAD1 (0.38) | TEAD1HSD17B10TEAD3JAK3FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | ISOCURE BIOSCIENCES INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | IDH1, IDH2, IDH3A | PIK3CD 651/4885MCHR1 4761/4885TEAD1 3585/4885 |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | IDH1, IDH2, IDH3A | PIK3CD 651/4885MCHR1 4761/4885TEAD1 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.